Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Biopharma Biotech Business Development
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Commercialization Consulting Resource Center
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization Consulting Resource Center
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization Consulting Resource Center

Biopharma

Real world data reveal how diseases manifest in diverse populations Real world data reveal how diseases manifest in diverse populations
Blog April 4, 2024
Real world data reveal how diseases manifest in diverse populations
Navigating Joint Clinical Assessment and the role of RWE in the new process Navigating Joint Clinical Assessment and the role of RWE in the new process
Blog March 29, 2024
Navigating Joint Clinical Assessment and the role of RWE in the new process
Rebates are likely driving U.S. payer coverage of GLP-1 agonists Rebates are likely driving U.S. payer coverage of GLP-1 agonists
Blog March 19, 2024
Rebates are likely driving U.S. payer coverage of GLP-1 agonists
Getting ahead of regulatory changes around PFAS in pharmaceutical packaging Getting ahead of regulatory changes around PFAS in pharmaceutical packaging
Blog March 14, 2024
Getting ahead of regulatory changes around PFAS in pharmaceutical packaging
Future-proofing drug R&D to ensure a successful commercial launch Future-proofing drug R&D to ensure a successful commercial launch
Blog March 12, 2024
Future-proofing drug R&D to ensure a successful commercial launch
Unleashing the power of computational tools in rare disease Unleashing the power of computational tools in rare disease
Blog February 28, 2024
Unleashing the power of computational tools in rare disease
Unlocking the potential of AI and machine learning for the life sciences Unlocking the potential of AI and machine learning for the life sciences
Blog February 5, 2024
Unlocking the potential of AI and machine learning for the life sciences
Pharma R&D productivity dips, but efficiency gains give hope Pharma R&D productivity dips, but efficiency gains give hope
Blog January 23, 2024
Pharma R&D productivity dips, but efficiency gains give hope
What sets the Drugs to Watch in 2024 apart What sets the Drugs to Watch in 2024 apart
Blog January 8, 2024
What sets the Drugs to Watch in 2024 apart
Five U.S. market access trends to watch in 2024 Five U.S. market access trends to watch in 2024
Blog December 15, 2023
Five U.S. market access trends to watch in 2024